pentadecapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Last but not least, specific cleavage of poly (ADP-ribose) polymerase (PARP) and a decrease in pro-caspase9 and 3 were also induced by arenobufagin treatment. PARP is mainly involved in cell repair and programmed cell death. After treatment with arenobufagin, some cells make more autophagosomes and lysosomes, whereas other cells undergo apoptosis. Arenobufagin also leads to increased expression of LC3-II, Biclin1(initial vesicle formation), Atg5 (elongation and completion), Atg9, Atg16L1 and p62/SQSTM1, all proteins which induce autophagy. Blockers of autophagy increase the cytotoxic effect of arenobufagin. Addition of 3-MA increases the proportion of cells in which there in enlarged PARP cleavage and limited caspase-9 and caspase-3 cleavage. This indicates that autophagy pathways protect the cell against apoptosis by arenobufagin. It was hypothesized that arenobufagin may inhibit the PI3K/Akt pathway in controlling cell death and differentiation in response to external stimuli. It was found that arenobufagin inhibited the proteins Akt, PDK1 and PI3K, whereas it stimulated the PHEN-protein. It does this by altering the degree of phosphorylation. All these proteins are involved in the PI3/Akt pathway. Further down the pathway, arenobufagin indirectly inhibits the mTOR-protein, which is involved in apoptosis as well as in autophagy. The biotransformation of arenobufagin by Alternaria alternata leads to the following three metabolites: 3-oxo-arenobufagin (1a), ψ-bufarenogin (1b), and 3- oxo- ψ-bufarenogin (1c).
Topical solutions can be marketed as drops, rinses, or sprays, are generally of low viscosity, and often use alcohol or water in the base. These are usually a powder dissolved in alcohol, water, and sometimes oil; although a solution that uses alcohol as a base ingredient, as in topical steroids, can cause drying of the skin. There is significant variability among brands, and some solutions may cause irritation, depending on the preservative(s) and fragrances used in the base. Some examples of topical solutions are given below:
=== Nervous system regeneration === Because of their implications in cellular motility and shape, Rho proteins became a clear target in the study of the growth cones that form during axonal generation and regeneration in the nervous system. Rho proteins may be a potential target for delivery into spinal cord lesions after traumatic injury. Following injury to the spinal cord, the extracellular space becomes inhibitory to the natural efforts neurons undergo to regenerate. These natural efforts include the formation of a growth cone at the proximal end of an injured axon. Newly formed growth cones subsequently attempt to "crawl" across the lesion. These are sensitive to chemical cues in the extracellular environment. One of the many inhibitory cues includes chondroitin sulfate proteoglycans (CSPGs). Neurons growing in culture become more able to cross regions of substrate coated with CSPG after expression of constitutively active Cdc42 or Rac1 or expression of a dominant negative form (inhibition) of RhoA. This is partly due to the exogenous Rho proteins driving cellular locomotion despite the extracellular cues promoting apoptosis and growth cone collapse. Intracellular modulation of Rho proteins has thus become of interest in research aimed at spinal cord regeneration.
Regional treatment centres had also been set up, with large increases in the number of infected in the South Pyongan and South Hamgyong provinces. On 20 May, 168 confirmed cases of COVID-19 were reported, with cases of reported fever nearing 2 million, according to NK News. On 3 June, NK News reported that GAVI had received information that North Korea had started its vaccination rollout with Chinese vaccines, with an anonymous source telling Radio Free Asia that the first doses were being administered to soldiers working in the construction sector. From around June, vehicles had started reappearing in satellite imagery in Pyongyang, which suggested that the lockdown was at least being partially lifted in Pyongyang, with a source alleging that restrictions were relaxed to allow for a few hours of outdoor time every day from late May, though provincial cities appeared to be still locked down.
Sources: en.wikipedia.org
=== Surgery === Surgery for back pain is typically used as a last resort, when serious neurological deficit is evident. A 2009 systematic review of back surgery studies found that, for certain diagnoses, surgery is moderately better than other common treatments, but the benefits of surgery often decline in the long term. Surgery may sometimes be appropriate for people with severe myelopathy or cauda equina syndrome. Causes of neurological deficits can include spinal disc herniation, spinal stenosis, degenerative disc disease, tumor, infection, and spinal hematomas, all of which can impinge on the nerve roots around the spinal cord. There are multiple surgical options to treat back pain, and these options vary depending on the cause of the pain. When a herniated disc is compressing the nerve roots, hemi- or partial-laminectomy or discectomy may be performed, in which the material compressing on the nerve is removed. A multi-level laminectomy can be done to widen the spinal canal in the case of spinal stenosis. A foraminotomy or foraminectomy may also be necessary, if the vertebrae are causing significant nerve root compression. A discectomy is performed when the intervertebral disc has herniated or torn. It involves removing the protruding disc, either a portion of it or all of it, that is placing pressure on the nerve root. Total disc replacement can also be performed, in which the source of the pain (the damaged disc) is removed and replaced, while maintaining spinal mobility.
She works with several biopharmaceutical companies to apply new mass spectrometry techniques to new drug modalities including monoclonal antibodies. She also develops new mass spectrometry instrumentation. Her group looks at the structure of biological systems at a molecular level, studying them in the gas and solution phase as well as theoretically. They use electrospray ionization, mass spectrometry, ion mobility mass spectrometry native mass spectrometry and complementary solution based biophysical techniques. They are interested in a proteins structure and how it changes in an effort to relate that to their function. Ion-mobility spectrometry–mass spectrometry can be used to look at the temperature dependent rotationally averaged collision cross-section of gas-phase ions of proteins. In 2014 she was awarded a Biotechnology and Biological Sciences Research Council grant to study the interactions of proteins with other proteins. Barran serves on the editorial board of the International Journal of Mass Spectrometry. She was included in the page of Perditas created by Perdita Stevens.
A vacuum flask (also known as a Dewar flask, Dewar bottle or thermos) is an insulating storage vessel that slows the speed at which its contents change in temperature. It greatly lengthens the time over which its contents remain hotter or cooler than the flask's surroundings by trying to be as adiabatic as possible. Invented by James Dewar in 1892, the vacuum flask consists of two flasks, placed one within the other and joined at the neck. The gap between the two flasks is partially evacuated of air, creating a near-vacuum which significantly reduces heat transfer by conduction or convection. When used to hold cold liquids, this also virtually eliminates condensation on the outside of the flask. Vacuum flasks are used domestically to keep contents inside hot or cold for extended periods of time. They are also used for thermal cooking. Vacuum flasks are also used for many purposes in industry.
Viserys I Targaryen is a fictional character in American author George R. R. Martin's the A Song of Ice and Fire series of epic fantasy novels, appearing in the 2013 novella The Princess and the Queen, the 2014 novella The Rogue Prince and the 2018 novel Fire & Blood. In the HBO television adaptation House of the Dragon, he is portrayed by English actor Paddy Considine. Viserys was the fifth king from the Targaryen dynasty to sit on the Iron Throne, ruling from 103 AC to 129 AC. He inherited the throne from his grandfather Jaehaerys I Targaryen, who had lost several previous heirs of his own issue. He is the older brother of Prince Daemon Targaryen, husband of queens Aemma Arryn and Alicent Hightower, and father of Queen Rhaenyra Targaryen and King Aegon II Targaryen. Ruling in a peacetime period, Viserys remained open-minded and approachable in addressing problems across the realm, and many lords and smallfolk praised him for his generosity. He hosted many tournaments, balls, and banquets in the Red Keep, a source of both unity and division depending on the occasion. He was not very physically active like Daemon, and dealt with various health problems that continued to worsen towards the end of his reign. The issue of succession caused much friction in Viserys' court, as he struggled to stabilize relations between the green faction led by Alicent and black faction led by Rhaenyra.
== Diagnosis == Lipedema requires diagnosis in a medical office by a clinician (a “clinical diagnosis”). A trained clinician reaches the diagnosis by considering patient history, including family history, and a physical exam. Clinicians should avoid reliance purely on differential diagnosis as this will lead to a failure to diagnose people with lipedema when they present with other co-morbidities like lymphedema, chronic venous insufficiency. There is not yet a standardized test, such as bloodwork or imaging, that can confirm the presence of lipedema, however, there are common clinical presentations that are specific to lipedema.
Sources: en.wikipedia.org
Resources for this airport: AirNav airport information for KMEM ASN accident history for MEM FlightAware airport information and live flight tracker NOAA/NWS weather observations: current, past three days SkyVector aeronautical chart for KMEM FAA current MEM delay information
Aspergillus luchuensis was first described in 1901 by Tamaki Inui at the University of Tokyo. Genichiro Kawachi isolated a colourless mutant of A. luchuensis (black kōji) in 1918 and named it Aspergillus kawachii (white kōji). Aspergillus sojae was first described as a distinct species in kōji in 1944. Initially, Aspergillus sojae was considered a variety of Aspergillus parasiticus because, unlike the other fungi of kōji, it had never been isolated from the soil.
===== MeSH D08.811.913.817 – sulfur group transferases (EC 2.8) ===== MeSH D08.811.913.817.200 – coenzyme a-transferases MeSH D08.811.913.817.400 – sulfotransferases MeSH D08.811.913.817.400.300 – aryl sulfotransferase MeSH D08.811.913.817.500 – sulfurtransferases MeSH D08.811.913.817.500.500 – thiosulfate sulfurtransferase
== Structure == Growth hormone receptor (GHR) is a transmembrane protein consisting of 620 amino acids. The receptor is part of the Type I cytokine receptor family of receptors. GHR exists in two forms as a full length membrane-bound receptor and as a soluble GH binding protein (GHBP). GHR contains two fibronectin type III β domains in its extracellular domain, whereas the intracellular domain contains tyrosine Kinase JAK2 binding sites for SH2 proteins. JAK2 is the primary signal transducer for growth hormone.
Seventeen isotopes of mendelevium are known, with mass numbers from 244 to 260; all are radioactive. The longest-lived isotope is 258Md with a half-life of 51.6 days. Nevertheless, the shorter-lived 256Md (half-life 77.7 minutes) is more often used in chemical experiments because it can be produced in larger quantities from einsteinium, as 258Md would require 255Es, of which significant quantities are available only as a minor component of an isotopic mixture. The half-lives of mendelevium isotopes mostly increase smoothly (apart from odd/even effects) toward higher mass, up to 258Md, then decrease (as indicated by what experimental data is available) as spontaneous fission becomes the dominant decay mode; the second longest-living isotope is 260Md, the heaviest known, with a half-life of 27.8 days. Mendelevium is the last element that has any known isotope with a half-life longer than a day. Mendelevium-256, the currently most important isotope of mendelevium, decays about 90% through electron capture and 10% through alpha decay. It is most easily detected through the spontaneous fission of its electron capture daughter fermium-256, but in the presence of other nuclides that undergo spontaneous fission, alpha decays at the characteristic energies for mendelevium-256 (7.205 and 7.139 MeV) can provide more useful identification.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.